Community-acquired methicillin-resistant Staphylococcus aureus

Journal of the American Academy of Dermatology

Volumn 56, Issue 1, 2007, Pages 1-16

  Elston, Dirk M ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BACITRACIN; BENZALKONIUM CHLORIDE; CEFTOBIPROLE MEDOCARIL; CETYLPYRIDINIUM SALT; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MEROPENEM; PANIPENEM; PLACEBO; POVIDONE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; RIFAMPICIN; SULFADIAZINE SILVER; TEA TREE OIL; TIGECYCLINE; TRICLOSAN; UNINDEXED DRUG; VANCOMYCIN;

AMERICAN INDIAN; ANTIBIOTIC RESISTANCE; ARMY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DAY CARE; DIARRHEA; DISEASE ASSOCIATION; DRUG ERUPTION; FOLLICULITIS; HOMELESSNESS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MEDICAL LITERATURE; NAUSEA; NONHUMAN; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PRISON; PRURITUS; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SKIN ABSCESS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRAINAGE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 33845698832     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.04.018     Document Type: Review

References (133)

1. Robinson D.A., and Enright M.C. Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 3926-3934
2. Lim T.T., Chong F.N., O'Brien F.G., and Grubb W.B. Are all community methicillin-resistant Staphylococcus aureus related? A comparison of their mec regions. Pathology 35 (2003) 336-343
3. Roghmann M., Taylor K.L., Gupte A., Zhan M., Johnson J.A., Cross A., et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp Infect 59 (2005) 27-32
4. van der Mee-Marquet N., Domelier A.S., Girard N., and Quentin R. Bloodstream Infection Study Group of the Relais d'Hygiene du Centre. Epidemiology and typing of Staphylococcus aureus strains isolated from bloodstream infections. J Clin Microbiol 42 (2004) 5650-5657
5. Udo E.E., Pearman J.W., and Grubb W.B. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 25 (1993) 97-108
6. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Mor Mortal Wkly Rep 52 (2003) 88
7. Kowalski T.J., Berbari E.F., and Osmon D.R. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 80 (2005) 1201-1207
8. Iyer S., and Jones D.H. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 50 (2004) 854-858
9. Diep B.A., Sensabaugh G.F., Somboona N.S., Carleton H.A., and Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 42 (2004) 2080-2084
10. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
11. Lu D., and Holtom P. Community-acquired methicillin-resistant Staphylococcus aureus, a new player in sports medicine. Curr Sports Med Rep 4 (2005) 265-270
12. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 41 Suppl 4 (2005) S269-S272
13. Charlebois E.D., Perdreau-Remington F., Kreiswirth B., Bangsberg D.R., Ciccarone D., Diep B.A., et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 39 (2004) 47-54
14. Cohen P.R. Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities. South Med J 98 (2005) 596-602
15. Mathews W.C., Caperna J.C., Barber R.E., Torriani F.J., Miller L.G., May S., et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr 40 (2005) 155-160
16. Tumbarello M., de Gaetano Donati K., Tacconelli E., Citton R., Spanu T., Leone F., et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother 50 (2002) 375-382
17. Pan E.S., Diep B.A., Charlebois E.D., Auerswald C., Carleton H.A., Sensabaugh G.F., et al. Population dynamics of nasal strains of methicillin-resistant Staphylococcus aureus-and their relation to community-associated disease activity. J Infect Dis 192 (2005) 811-818
18. Carleton H.A., Diep B.A., Charlebois E.D., and Sensabaugh G.F. Perdreau-Remington F. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis 190 (2004) 1730-1738
19. Buckingham S.C., McDougal L.K., Cathey L.D., Comeaux K., Craig A.S., Fridkin S.K., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee, Children's Hospital. Pediatr Infect Dis J 23 (2004) 619-624
20. Purcell K., and Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 159 (2005) 980-985
21. Frazee B.W., Lynn J., Charlebois E.D., Lambert L., Lowery D., and Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 45 (2005) 311-320
22. Stemper M.E., Shukla S.K., and Reed K.D. Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin, 1989 to 1999. J Clin Microbiol 42 (2004) 5673-5680
23. Baggett H.C., Hennessy T.W., Leman R., Hamlin C., Bruden D., Reasonover A., et al. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 24 (2003) 397-402
24. Dietrich D.W., Auld D.B., and Mermel L.A. Community-acquired methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics 113 (2004) e347-e352
25. Said-Salim B., Mathema B., and Kreiswirth B.N. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 24 (2003) 451-455
26. Baba T., Takeuchi F., Kuroda M., Yuzawa H., Aoki K., Oguchi A., et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359 (2002) 1819-1827
27. Tirabassi M.V., Wadie G., Moriarty K.P., Garb J., Konefal S.H., Courtney R.A., et al. Geographic information system localization of community-acquired MRSA soft tissue abscesses. J Pediatr Surg 40 (2005) 962-965
28. Kitai S., Shimizu A., Kawano J., Sato E., Nakano C., Uji T., et al. Characterization of methicillin-resistant Staphylococcus aureus isolated from retail raw chicken meat in Japan. J Vet Med Sci 67 (2005) 107-110
29. Kourbatova E.V., Halvosa J.S., King M.D., Ray S.M., White N., and Blumberg H.M. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 33 (2005) 385-391
30. Naas T., Fortineau N., Spicq C., Robert J., Jarlier V., and Nordmann P. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital. J Hosp Infect 61 (2005) 321-329
31. Saiman L., O'Keefe M., Graham III P.L., Wu F., Said-Salim B., Kreiswirth B., et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 37 (2003) 1313-1319
32. Eckhardt C., Halvosa J.S., Ray S.M., and Blumberg H.M. Transmission of methicillin-resistant Staphylococcus aureus in the neonatal intensive care unit from a patient with community-acquired disease. Infect Control Hosp Epidemiol 24 (2003) 460-461
33. Salgado C.D., Farr B.M., and Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 36 (2003) 131-139
34. Huang Y.C., Su L.H., Chen C.J., and Lin T.Y. Nasal carriage of methicillin-resistant Staphylococcus aureus in school children without identifiable risk factors in northern Taiwan. Pediatr Infect Dis J 24 (2005) 276-278
35. Jernigan J.A., Pullen A.L., Flowers L., Bell M., and Jarvis W.R. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus at the time of hospital admission. Infect Control Hosp Epidemiol 24 (2003) 409-414
36. Lesens O., Hansmann Y., Brannigan E., Hopkins S., Meyer P., O'Connel B., et al. Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate?. Infect Control Hosp Epidemiol 26 (2005) 204-209
37. Reed S.D., Friedman J.Y., Engemann J.J., Griffiths R.I., Anstrom K.J., Kaye K.S., et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26 (2005) 175-183
38. Calfee D.P., Durbin L.J., Germanson T.P., Toney D.M., Smith E.B., and Farr B.M. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 24 (2003) 422-426
39. Ellis M.W., Hospenthal D.R., Dooley D.P., Gray P.J., and Murray C.K. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 39 (2004) 971-979
40. Laibl V.R., Sheffield J.S., Roberts S., McIntire D.D., Trevino S., and Wendel Jr. G.D. Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy. Obstet Gynecol 106 (2005) 461-465
41. Miller L.G., Perdreau-Remington F., Rieg G., Mehdi S., Perlroth J., Bayer A.S., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352 (2005) 1445-1453
42. Baggett H.C., Hennessy T.W., Rudolph K., Bruden D., Reasonover A., Parkinson A., et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 189 (2004) 1565-1573
43. Kazakova S.V., Hageman J.C., Matava M., Srinivasan A., Phelan L., Garfinkel B., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352 (2005) 468-475
44. Gonzalez B.E., Martinez-Aguilar G., Hulten K.G., Hammerman W.A., Coss-Bu J., Avalos-Mishaan A., et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115 (2005) 642-648
45. Gonzalez B.E., Hulten K.G., Dishop M.K., Lamberth L.B., Hammerman W.A., Mason Jr. E.O., et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 41 (2005) 583-590
46. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
47. Lee M.C., Rios A.M., Aten M.F., Mejias A., Cavuoti D., McCracken Jr. G.H., et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23 (2004) 123-127
48. Young D.M., Harris H.W., Charlebois E.D., Chambers H., Campbell A., Perdreau-Remington F., et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 139 (2004) 947-951
49. Rutar T., Zwick O.M., Cockerham K.P., and Horton J.C. Bilateral blindness from orbital cellulitis caused by community-acquired methicillin-resistant Staphylococcus aureus. Am J Ophthalmol 140 (2005) 740-742
50. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 11 Suppl 3 (2005) 29-35
51. Boyle-Vavra S., Ereshefsky B., Wang C.C., and Daum R.S. Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J Clin Microbiol 43 (2005) 4719-4730
52. Braun L., Craft D., Williams R., Tuamokumo F., and Ottolini M. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 24 (2005) 622-626
53. O'Sullivan M.V., Cai Y., Kong F., Zeng X., and Gilbert G.L. Influence of disk separation distance on accuracy of the disk approximation test for detection of inducible clindamycin resistance in Staphylococcus spp. J Clin Microbiol 44 (2006) 4072-4076
54. Buescher E.S. Community-acquired methicillin-resistant Staphylococcus aureus in pediatrics. Curr Opin Pediatr 17 (2005) 67-70
55. Marcinak J.F., and Frank A.L. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis 16 (2003) 265-269
56. Patel M., Waites K.B., Moser S.A., Cloud G.A., and Hoesley C.J. Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J Clin Microbiol 44 (2006) 2481-2484
57. Siberry G.K., Tekle T., Carroll K., and Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37 (2003) 1257-1260
58. Lewis II J.S., and Jorgensen J.H. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned?. Clin Infect Dis 40 (2005) 280-285
59. Sattler C.A., Mason Jr. E.O., and Kaplan S.L. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 21 (2002) 910-917
60. Martinez-Aguilar G., Hammerman W.A., Mason Jr. E.O., and Kaplan S.L. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22 (2003) 593-598
61. Chavez-Bueno S., Bozdogan B., Katz K., Bowlware K.L., Cushion N., Cavuoti D., et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 49 (2005) 2283-2288
62. Kaplan S.L., Hulten K.G., Gonzalez B.E., Hammerman W.A., Lamberth L., Versalovic J., and Mason Jr. E.O. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 40 (2005) 1785-1791
63. Levin T.P., Suh B., Axelrod P., Truant A.L., and Fekete T. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrobial Agents Chemother 49 (2005) 1222-1224
64. Wang C.C., Lo W.T., Chu M.L., and Siu L.K. Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus isolates from children in Taiwan. Clin Infect Dis 39 (2004) 481-487
65. Sabol K.E., Echevarria K.L., and Lewis II J.S. Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother 40 (2006) 1125-1133
66. Frank A.L., Marcinak J.F., Mangat P.D., Tjhio J.T., Kelkar S., Schreckenberger P.C., et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 21 (2002) 530-534
67. Chen C.J., Huang Y.C., Chiu C.H., Su L.H., and Lin T.Y. Clinical features and genotyping analysis of community-acquired methicillin-resistant Staphylococcus aureus infections in Taiwanese children. Pediatr Infect Dis J 24 (2005) 40-45
68. O'Donoghue M.M., and Boost M.V. The prevalence and source of methicillin-resistant Staphylococcus aureus (MRSA) in the community in Hong Kong. Epidemiol Infect 132 (2004) 1091-1097
69. Takizawa Y., Taneike I., Nakagawa S., Oishi T., Nitahara Y., Iwakura N., et al. A Panton-Valentine leucocidin (PVL)-positive community-acquired methicillin-resistant Staphylococcus aureus (MRSA) strain, another such strain carrying a multiple-drug resistance plasmid, and other more-typical PVL-negative MRSA strains found in Japan. J Clin Microbiol 43 (2005) 3356-3363
70. Shelburne S.A., Musher D.M., Hulten K., Ceasar H., Lu M.Y., Bhaila I., et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48 (2004) 4016-4019
71. Marangon F.B., Miller D., Muallem M.S., Romano A.C., and Alfonso E.C. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 137 (2004) 453-458
72. Horii T., Suzuki Y., Monji A., Morita M., Muramatsu H., Kondo Y., et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 46 (2003) 139-145
73. Venezia R.A., Domaracki B.E., Evans A.M., Preston K.E., and Graffunder E.M. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 48 (2001) 375-381
74. Harbarth S., Liassine N., Dharan S., Herrault P., Auckenthaler R., and Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 31 (2000) 1380-1385
75. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., and Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9 (2003) 1415-1422
76. MacDougall C., Harpe S.E., Powell J.P., Johnson C.K., Edmond M.B., and Polk R.E. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 11 (2005) 1197-1204
77. MacDougall C., Powell J.P., Johnson C.K., Edmond M.B., and Polk R.E. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 41 (2005) 435-440
78. Gilbert D.N., Kohlhepp S.J., Slama K.A., Grunkemeier G., Lewis G., Dworkin R.J., et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 45 (2001) 883-892
79. Cunha B.A. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 Suppl 4 (2005) 33-42
80. Tally F.P., Zeckel M., Wasilewski M.M., Carini C., Berman C.L., Drusano G.L., et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 8 (1999) 1223-1238
81. Hsueh P.R., Chen W.H., Teng L.J., and Luh K.T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 26 (2005) 43-49
82. LaPlante K.L., and Rybak M.J. Daptomycin-a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 5 (2004) 2321-2331
83. Mangili A., Bica I., Snydman D.R., and Hamer D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 (2005) 1058-1060
84. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., and Weinstein R.A. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5285-5287
85. Scotton P.G., Rigoli R., and Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection 30 (2002) 161-163
86. Yanagihara K., Okada M., Fukuda Y., Imamura Y., Kaneko Y., Ohno H., et al. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. Chemotherapy 50 (2004) 260-264
87. El-Azizi M., Rao S., Kanchanapoom T., and Khardori N. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 4 (2005) 2
88. Millan L., Cerda P., Rubio M.C., Goni P., Canales M., Capilla S., Oca M., et al. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates. J Chemother 16 (2004) 230-237
89. Sander A., Beiderlinden M., Schmid E.N., and Peters J. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 28 (2002) 1157-1160
90. Goff D.A., and Sierawski S.J. Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections. Pharmacotherapy 22 (2002) 748-758
91. Brown J., and Freeman III B.B. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother 38 (2004) 677-685
92. Munoz Bellido J.L., Gutierrez Zufiaurre M.N., Sanchez Hernandez F.J., Yague Guirao G., Segovia Hernandez M., and Garcia-Rodriguez J.A. In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 20 (2002) 61-64
93. Luh K.T., Hsueh P.R., Teng L.J., Pan H.J., Chen Y.C., Lu J.J., et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 44 (2000) 3374-3380
94. Imamura H., Ohtake N., Jona H., Shimizu A., Moriya M., Sato H., et al. Dicationic dithiocarbamate carbapenems with anti-MRSA activity. Bioorg Med Chem 9 (2001) 1571-1578
95. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 11 (2005) 259-261
96. Wilson S.E. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. Surg Infect (Larchmt) 2 (2001) 25-35
97. Machado A.R., Arns Cda C., Follador W., and Guerra A. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis 9 (2005) 191-200
98. Plosker G.L., and Figgitt D.P. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections. Pharmacoeconomics 23 (2005) 945-964
99. Grau S., Alvarez-Lerma F., del Castillo A., Neipp R., and Rubio-Terres C. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother 17 (2005) 203-211
100. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
101. Sharpe J.N., Shively E.H., and Polk Jr. H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 (2005) 425-428
102. Li J.Z., Willke R.J., Rittenhouse B.E., and Rybak M.J. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 4 (2003) 57-70
103. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
104. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 52 (2005 Jul) 195-201
105. Livermore D.M. Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56 (2005) 611-614
106. Sacchidanand S., Penn R.L., Embil J.M., Campos M.E., Curcio D., Ellis-Grosse E., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9 (2005) 251-261
107. Breedt J., Teras J., Gardovskis J., Maritz F.J., Vaasna T., Ross D.P., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 (2005) 4658-4666
108. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
109. Vaudaux P., Gjinovci A., Bento M., Li D., Schrenzel J., and Lew D.P. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 3789-3793
110. von Eiff C., Friedrich A.W., Becker K., and Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 49 (2005) 4372-4374
111. Upton A., Lang S., and Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 51 (2003) 613-617
112. Mulvey M.R., MacDougall L., Cholin B., Horsman G., Fidyk M., Woods S., et al. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 11 (2005) 844-850
113. Harbarth S., Dharan S., Liassine N., Herrault P., Auckenthaler R., and Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1412-1416
114. Dryden M.S., Dailly S., and Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 56 (2004) 283-286
115. Irish D., Eltringham I., Teall A., Pickett H., Farelly H., Reith S., et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 39 (1998) 19-26
116. Kanazawa K., and Ueda Y. Bactericial activity of chlorhexidine gluconate against recent clinical isolates of various bacterial species in Japan. Jpn J Antibiot 57 (2004) 449-464
117. Zhang Y.H., Liu X.Y., Zhu L.L., and Yu Y.Z. Study on the resistance of methicillin-resistant Staphylococcus aureus to iodophor and chlorhexidine. Zhonghua Liu Xing Bing Xue Za Zhi 25 (2004) 248-250
118. Block C., Robenshtok E., Simhon A., and Shapiro M. Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis using a surface test. J Hosp Infect 46 (2000) 147-152
119. Suller M.T., and Russell A.D. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect 43 (1999) 281-291
120. Kampf G., Jarosch R., and Ruden H. Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 38 (1998) 297-303
121. Suzuki J., Komatsuzawa H., Kozai K., and Nagasaka N. In vitro susceptibility of Staphylococcus aureus including MRSA to four disinfectants. ASDC J Dent Child 64 (1997) 260-263
122. Gordin F.M., Schultz M.E., Huber R.A., and Gill J.A. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 26 (2005) 650-653
123. Brenwald N.P., and Fraise A.P. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 55 (2003) 141-144
124. Bamber A.I., and Neal T.J. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect 41 (1999) 107-109
125. Lambert R.J. Comparative analysis of antibiotic and antimicrobial biocide susceptibility data in clinical isolates of methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa between 1989 and 2000. J Appl Microbiol 97 (2004) 699-711
126. Noguchi N., Suwa J., Narui K., Sasatsu M., Ito T., Hiramatsu K., et al. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol 54 Pt 6 (2005) 557-565
127. Fraise A.P. Susceptibility of antibiotic-resistant cocci to biocides. Symp Ser Soc Appl Microbiol 31 (2002) 158S-162S
128. Suller M.T., and Russell A.D. Triclosan and antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 46 (2000) 11-18
129. Zafar A.B., Butler R.C., Reese D.J., Gaydos L.A., and Mennonna P.A. Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. Am J Infect Control 23 (1995) 200-208
130. Brady L.M., Thomson M., Palmer M.A., and Harkness J.L. Successful control of endemic MRSA in a cardiothoracic surgical unit. Med J Aust 152 (1990) 240-245
131. Webster J., Faoagali J.L., and Cartwright D. Elimination of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit after hand washing with triclosan. J Paediatr Child Health 30 (1994) 59-64
132. Webster J. Handwashing in a neonatal intensive care nursery: product acceptability and effectiveness of chlorhexidine gluconate 4% and triclosan 1%. J Hosp Infect 21 (1992) 137-141
133. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J.C., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin Infect Dis 41 (2005) 1373-1406